Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL8379309 | 0.96 | ESR1 (0.42) | ESR1ESR2EPHX1KDM1AEPHX2 | |
| SCHEMBL3879605 | 0.92 | ESR1 (0.41) | ESR1ESR2EPHX1KDM1AEPHX2 | |
| SCHEMBL10124069 | 0.87 | ESR1 (0.50) | ESR1ESR2EPHX1KDM1ACNR1 | |
| SCHEMBL25026044 | 0.80 | ESR1 (0.44) | ESR1ESR2EPHX1KDM1AEPHX2 | |
| SCHEMBL8164423 | 0.80 | — | — | |
| SCHEMBL1470211 | 0.80 | EPHX1 (0.42) | ESR1ESR2EPHX1KDM1AEPHX2 | |
| SCHEMBL1135314 | 0.77 | HDAC6 (0.45) | MAPK1LIPERIPK1KMT2A | |
| SCHEMBL1902961 | 0.75 | ALDH1A1 (0.42) | ESR1ESR2EPHX1KDM1AEPHX2 | |
| SCHEMBL4406128 | 0.75 | MLYCD (0.45) | ESR1ESR2EPHX1EPHX2KMT2A | |
| SCHEMBL506139 | 0.75 | ESR1 (0.59) | ESR1ESR2KDM1ARIPK1ABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559506-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250263491-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-08-21 | — | — | US | disclosed |
| CN-118994163-A | Compounds containing a fused ring structure | 正大天晴药业集团股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20240360152-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-10-31 | — | — | US | disclosed |
| US-11981683-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4308557-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-117321046-A | Indazole-based compounds and related methods of use | 阿维纳斯企业公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230339949-A1 | HETEROCYCLIC SUBSTITUTED FUSED y-CARBOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF AND USE THEREOF | SHUJING BIOPHARMA CO., LTD (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230339949-A1 | HETEROCYCLIC SUBSTITUTED FUSED y-CARBOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF AND USE THEREOF | SHUJING BIOPHARMA CO., LTD (CN) | 2023-10-26 | — | — | US | disclosed |
| EP-4227306-A1 | HETEROCYCLIC SUBSTITUTED FUSED GAMMA-CARBOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF AND USE THEREOF | Shujing Biopharma Co., Ltd (CN) | 2023-08-16 | — | — | EP | disclosed |
| US-20020055508-A1 | Treating memory impairment; enhance excitatory synaptic activity in order to restore an imbalance between brain subregions, as in treatment of schizophrenia or schizophreniform behavior. | CORTEX PHARMACEUTICALS, INC. | 2002-05-09 | — | — | US | disclosed |
| US-20020004513-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2002-01-10 | — | — | US | disclosed |
| US-6313115-B1 | ALLEVIATE IMPAIRMENT OF MEMORY, OR OTHER COGNITIVE FUNCTIONS CAUSED BY HYPOGLUTAMATERGIC CONDITION OR BY DEFICIENCY IN NUMBER OR STRENGTH OF EXCITATORY SYNAPSES OR IN NUMBER OF AMPA RECEPTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-11-06 | — | — | US | disclosed |
| WO-2001066521-A1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARMACEUTICALS, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
| US-6110935-A | A PROMOTER FOR N-METHYL-D-ASPARTIC ACID (NMDA) RECEPTORS, USEFUL FOR SUCH THERAPEUTIC PURPOSES AS FACILITATING THE LEARNING OF BEHAVIORS, TREATING SCHIZOPHRENIA, MEMORY IMPAIRMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-08-29 | — | — | US | disclosed |
| EP-0960105-A1 | BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY | The Regents of the University of California (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1998035950-A1 | BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY | CORTEX PHARMACEUTICALS, INC. (US) | 1998-08-20 | — | — | WO | disclosed |
| EP-0290744-B1 | ANTHRACYCLINE COMPOUNDS AND USE THEREOF | KIRIN BEER KABUSHIKI KAISHA (JP) | 1993-06-09 | — | — | EP | disclosed |
| US-4888418-A | ANTITUMOR AGENTS | KIRIN BEER KABUSHIKI KAISHA (JP) | 1989-12-19 | — | — | US | disclosed |
| EP-0290744-A2 | Anthracycline compounds and use thereof | KIRIN BEER KABUSHIKI KAISHA (JP) | 1988-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360152-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | ESR1 3736/4885ESR2 2752/4885EPHX1 4404/4885 |
| US-12559506-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, CLK2 | ESR1 3546/4885ESR2 3660/4885EPHX1 4819/4885 |
| US-20250263491-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | ESR1 553/4885ESR2 632/4885EPHX1 1775/4885 |
| US-20020004513-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | ESR1 1501/4885ESR2 518/4885EPHX1 2380/4885 |
| US-20020055508-A1 | Treating memory impairment; enhance excitatory synaptic activity in order to restore an imbalance between brain subregions, as in treatment of schizophrenia or schizophreniform behavior. | GRIN1, GABRE, GRM1 | ESR1 804/4885ESR2 276/4885EPHX1 566/4885 |
| US-11981683-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, MDM2 | ESR1 3736/4885ESR2 2752/4885EPHX1 4404/4885 |
| US-20230339949-A1 | HETEROCYCLIC SUBSTITUTED FUSED y-CARBOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF AND USE THEREOF | WEE1, FARS2, WEE2 | ESR1 3415/4885ESR2 3232/4885EPHX1 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.